Bugs as drugs – Innovating in the Microbiome space

2025-05-06T12:41:28+01:006 May 2025|

We spoke to Dr Trevor Lawley, Senior Group Leader at the Wellcome Sanger Institute who works in the Parasites and Microbes Programme.  Trevor’s is the story of turning basic, fundamental research into innovative science with potential to treat a broad range of human diseases.

Microbiotica: CASE STUDY

2025-01-16T14:21:41+00:001 December 2024|

Based originally upon the research of the human microbiome carried out at the Wellcome Sanger Institute, Microbiotica was spun out as a microbiome therapeutics company in 2016. Today, Microbiotica is advancing steadily towards introducing transformational microbiome-based therapeutics and biomarkers in areas of high medical need, with first clinical trials – underpinned by a landmark £50m investment during 2022 – starting soon.

Personalising cancer treatment using the gut microbiome

2024-09-06T10:23:10+01:006 September 2024|

Did you know that your gut bugs may affect your cancer risk? Dr Ashray Gunjur, Clinical Research Training Fellow at the Wellcome Sanger Institute, is exploring how clinicians can use the biology of the gut microbiome to personalise cancer treatment.

20 Things We Learned in 2020

2021-11-08T11:50:04+00:0021 December 2020|

This has been a year that none of us will forget in a hurry. The Institute is immensely proud of the way our staff have pulled together, and the work we have managed to achieve